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The absence of effective vaccines against malaria and the difficulties associated with 
controlling mosquito vectors have left chemotherapy as the primary control measure 
against malaria. However, the emergence and spread of parasite resistance to con-
ventional antimalarial drugs result in a worrisome scenario making the search for 
new drugs a priority. In the present study, the activities of nine neolignan derivatives 
were evaluated as follows: (i) against blood forms of chloroquine- resistant 
Plasmodium falciparum (clone W2), using the tritiated hypoxanthine incorporation 
and anti- HRPII assays; (ii) for cytotoxic activity against cultured human hepatoma 
cells (HepG2); and (iii) for intermolecular interaction with the P. falciparum cysteine 
protease of falcipain- 2 (F2) by molecular docking. The neolignan derivatives 9 and 
10 showed activity against the blood form of the chloroquine- resistant P. falciparum 
clone W2 and were not cytotoxic against cultured human hepatoma cells. A molecu-
lar docking study of these two neolignans with FP2 revealed several intermolecular 
interactions that should guide the design of future analogs.
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1 |  INTRODUCTION
Malaria is the leading public health problem among trans-
missible diseases in the world. According to the 2015 World 
Malaria Report, there were around 214 million cases of human 
malaria with 438,000 reported deaths.[1] Despite various at-
tempts not completely successful to produce a vaccine, che-
motherapy remains the main control tool against the disease.[2] 
However, multiresistance of Plasmodium falciparum against 
antimalarial compounds and the lower sensitivity of P. vivax 
to chloroquine have been important obstacles to preventing 
spread of the disease.[3] Many efforts have been made toward 
identifying novel molecular targets for development of new 
compounds against malaria. One attractive target is a cyste-
ine protease of P. falciparum, falcipain- 2 (FP2), an essential 
enzyme for parasite development.[4] FP2 is particularly suited 
for the hydrolysis of native hemoglobin in the acidic food vac-
uole, and several studies reveal that cysteine protease inhibi-
tors such as chalcones block globin hydrolysis by inhibition 
of FP2[5,6]; however, most chalcones exhibit high toxicity.[7,8]
The neolignans correspond to a kind of lignoids derived 
from the oxidative homo- or cross- coupling of alylphenols 
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and propenyl phenols.[9] They are found in plants from the 
Miristicaceae family,[10] and have demonstrated antibacte-
rial,[11] anti- Schistosoma,[12,13] antifungal,[14] trypanosomi-
cidal, anti- Plasmodium,[15,16] and leishmanicida[17] activities. 
Neolignan derivatives are active against Plasmodium at 
nanomolar concentrations, and are considered the most ac-
tive lignoids against malaria, thus promising antimalarial 
prototypes.[15,16,18]
In an attempt to identify non- toxic FP2 inhibitors retaining 
good activity, novel neolignan derivatives were synthesized 
based on their structural similarity with chalcones. Nine neo-
lignan derivatives were tested against chloroquine- resistant 
P. falciparum blood forms (clone W2). The inhibitory drug 
concentration that eliminates 50% of the parasites was de-
termined using the anti- HRPII (histidine- rich protein II) and 
hypoxanthine- tritiated incorporation assays, in parallel with 
tests of drug cytotoxicity to HepG2 cells (MDL50) to calcu-
late their selectivity indexes (SI). The best compounds were 
subjected to theoretical docking studies with the FP2.
2 |  METHODS AND MATERIALS
2.1 | Experimental section
2.1.1 | Material
The reactions were monitored by thin- layer chromatography 
performed on TLC plates with silica gel 60 F254 (Merck®). 
The spectra data 1H (62.5, 400, and 500 MHz) and 13C (50, 
100, and 125 MHz) were obtained by Bruker AC 250/P, 
Bruker Avance 400 and Varian Inova- 500, using CDCl3 and 
DMSO- d6 as solvents and TMS as the internal standard (chem-
ical shift δ in ppm). The infrared absorption spectra were ob-
tained using a spectrophotometer Bomen Model MB Series 
II, and mass spectra (MS) were evaluated on VG AutoSpec 
high- resolution mass spectrometer (Micromass Company).
2.2 | Synthesis
2.2.1 | Compound preparation (4, 5, 7–10)
A solution of 1.02 equivalent of phenol derivative in anhy-
drous ethyl methyl ketone (4.5 ml of solvent/mmol of α- 
bromoketone) and 1.80 equivalent of anhydrous K2CO3 was 
stirred for 10 min at room temperature, and then a solution 
of α- bromoketone in anhydrous ethyl methyl ketone (1.5 ml 
of solvent/mmol of α- bromoketone) was added dropwise. The 
reaction mixture was stirred and refluxed for 12 hr. After com-
pletion, the mixture was concentrated under vacuum, diluted 
with H2O, and extracted with CHCl3 (3×). The organic layer 
was washed with water, 5% NaOH solution, brine, and dried 
over Na2SO4. The solvent was evaporated to result in a crude 
product which was purified by crystallization from ethanol.
2- Oxo- 2- phenylethyl (2E)- 3- [4- (2- oxo- 2- phenylethoxy)
phenyl]prop- 2- enoate 4
This compound was obtained from 0.42 g (2.56 mmol) of 
4- hydroxycinnamic acid, 0.50 g (2.51 mmol) of phenacyl 
bromide, and 0.625 g (4.52 mmol) of K2CO3. The prod-
uct obtained was a colorless crystalline solid (0.160 g). 
Yield 32%. M.P. 145–147°C. 1H NMR (400 MHz, DMSO) 
δ: 7.99 (d, J = 7.4 Hz, 2H), 8.04 (d, J = 7.4 Hz, 2H), 7.70 
(d, J = 16.0 Hz, 1H), 7.60–7.73 (m, 4H), 7.59–7.55 (td, 
J = 7.4 Hz and J = 2.7 Hz, 4H), 7.04 (d, J = 9.0 Hz, 2H), 
6.64 (d, J = 16.0 Hz, 1H), 5.68 (s, 2H), 5.60 (s, 2H).13C 
NMR (100 MHz, DMSO) δ: 194.2, 193.0, 165.9, 160.0, 
145.1, 134.3, 134.0, 130.2, 128.9, 128.9, 127.9, 127.8, 126.9, 
115.1, 114.8, 70.2, 66.4. HRMS (ESI): calcd for C25H21O5
+ 
[M + H]+ 401.1384, found 401,1389. IR (KBr, cm−1): 1721 
(C=O), 1706 (C=O).
2- Oxo- 2- phenylethyl 4- (2- oxo- 2- phenylethoxy)
benzoate 5
This compound was obtained from 0.35 g (2.56 mmol) of 
4- hydroxybenzoic acid, 0.50 g (2.51 mmol) of phenacyl 
bromide, and 0.62 g (4.52 mmol) of K2CO3. The product 
obtained was a white crystalline solid (0.16 g). Yield 34%. 
M.P. 146–148°C. 1H NMR (400 MHz, DMSO) δ: 8.07 (d, 
J = 9.0 Hz, 2H), 7.98 (d, J = 8.5 Hz, 2H), 7.94 (d, J = 8.5 Hz, 
2H), 7.46–7.52 (m, 4H), 6.97 (d, J = 9.0 Hz, 2H), 5.52 (s, 
2H), 5,50 (s, 2H). 13C NMR (100 MHz, DMSO) δ: 193.6, 
192.3, 165.5, 162.0, 134.4, 134.3, 134.1, 133.8, 132.1, 128.9, 
128.9, 128.1, 127.8, 122.7, 114.5, 70.5, 66.3. HRMS (ESI): 
calcd for C23H18NaO5
+ [M+Na]+397.1046, found 397.1089. 
IR (KBr, cm−1): 1716 (C=O), 1698 (C=O).
2- Oxo- 2- phenylethyl (2E)- 3- (1,3- benzodioxol- 5- yl)
prop- 2- enoate 7
This compound was obtained from 0.50 g (2.56 mmol) of 
3,4- (methylenedioxy)cinnamic acid, 0.50 g (2.51 mmol) of 
phenacyl bromide, and 0.62 g (4.52 mmol) of K2CO3. The 
product obtained was a colorless crystalline solid (0.54 g). 
Yield 69%. M.P. 144–146°C. 1H NMR (400 MHz, CDCl3) δ: 
5.46 (s, 2H), 6.01 (s, 2H), 6.42 (d, J = 16.0 Hz, 1H), 6.81 (d, 
J = 7.9 Hz, 1H), 7.01–7.05 (m, 2H), 7.49 (t, J = 7.9 Hz, 2H), 
7.61 (t, J = 7.3 Hz, 1H), 7.82 (d, J = 16.0 Hz,1H), 7.95 (d, 
J = 7.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ: 66.0, 101.6, 
106.6, 108.5, 114.8, 124.7, 127.8, 128.7, 128.8, 129.2, 133.8, 
134.3, 145.8, 148.3, 149.8, 166.4, 192.4. HRMS (ESI): calcd 
for C18H14KO5
+[M+K]+349.0473, found 349.0478. IR (KBr, 
cm−1): 1715 (C=O), 1694 (C=O).
2- (4- chlorophenyl)- 2- oxoethyl (2E)- 3- (3,4,5- 
trimethoxyphenyl)prop- 2- enoate 8
This compound was obtained from 1.04 g (4.36 mmol) 
of 3,4,5- trimethoxycinnamic acid, 1.0 g (4.28 mmol) of 
2- bromo- 4′- chloroacetophenone, and 1.1 g (7.74 mmol) of 
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K2CO3. The product obtained was a colorless crystalline solid 
(0.75 g). Yield 45%. M.P. 117–119°C. 1H NMR (400 MHz, 
CDCl3) δ: 7.90 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 16.0 Hz, 
1H), 7.48–7.46 (m, 2H), 6.78 (s, 2H), 6.50 (d, J = 16.0 Hz, 
1H), 5.44 (s, 2H), 3.89 (s, 9H). 13C NMR (100 MHz, CDCl3) 
δ: 191.2, 166.1, 153.3, 146.2, 140.3, 140.3, 132.5, 129.6, 
129.1, 115.9, 105.4, 65.8, 60.9, 56.1.HRMS (ESI): calcd for 
C20H20ClO6
+[M+H]+391.0943, found 391.0948. IR (KBr, 
cm−1): 1714 (C=O), 1629 (C=O).
Methyl- (2E)- 3- [3- methoxy- 4- (2- oxo- 2- phenylethoxy)
phenyl]prop- 2- enoate 9
This compound was obtained from 0.77 g (3.71 mmol) of me-
thyl ferulate, 0.70 g (0.35 mmol) of 8- bromoacetophenone, 
and 0.87 g (6.33 mmol) of K2CO3. The product obtained was 
a brown crystalline solid (0.37 g). Yield 32%. M.P. 105–
107°C. 1H NMR (500 MHz, CDCl3) δ: 8.00 (d, J = 8.0 Hz, 
2H), 7.63–7.59 (m, 2H), 7.50 (t, J1 = 8.0 Hz, 2H), 7.07 (s, 
1H), 7.02 (d, J1 = 8.0 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 
6.31 (d, J = 16.0 Hz, 1H), 5.41 (s, 2H), 3.92 (s, 3H), 3.79 
(s, 3H). 13C NMR (125 MHz, CDCl3) δ: 193.7, 167.5, 149.5, 
149.3, 144.5, 134.2, 133.9, 128.8, 128.5, 127.9, 122.0, 
115.9, 113.6, 110.4, 71.3, 55.9, 51.6. HRMS (ESI): calcd 
for C19H19O5
+[M+H]+ 327.1227, found 327.1233. IR (KBr, 
cm−1): 1721.4 (C=O), 1689.7 (C=O).
1- (4- methoxyphenyl)- 1- oxopropan- 2- yl- (2E)- 3- (4- {[1- 
(4- methoxyphenyl)- 1- oxopropan- 2- yl]oxy}phenyl)
prop- 2- enoate 10
This compound was obtained from 0.18 g (1.05 mmol) 
of 4- hydroxycinnamic acid, 0.25 g (1.03 mmol) of 
4- methoxy- 8- bromopropiophenone, and 0.27 g (1.98 mmol) 
of K2CO3. The product obtained was a white crystalline solid 
(0.18 g). Yield 71%. M.P. 142–144°C. 1H NMR (400 MHz, 
DMSO) δ: 8.12 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 
7.70 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 16.0 Hz, 1H), 7.19–
7.08 (m, 4H), 6.94 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 16.0 Hz, 
1H), 6.16–6.06 (m, 2H), 3.91 (s, 3H), 3.90 (s, 3H), 1.59 
(d, J = 7.0 Hz, 3H), 1.52 (d, J = 7.0 Hz, 3H). 13C NMR 
(100 MHz, DMSO) δ: 196.1, 195.1, 165.8, 163.8, 163.6, 
159.2, 144.9, 130.9, 130.8, 130.3, 126.9, 126.7, 126.7, 115.3, 
115.0, 114.3, 114.2, 74.3, 71.2, 55.7, 18.5, 17.2. 13C NMR – 
(63 MHz, DMSO) δ: 196.1, 195.1, 165.8, 163.8, 163.6, 159.2, 
144.9, 131.0, 130.8, 130.3, 126.9, 126.7, 126.7, 115.3, 115.0, 
114.3, 114.3, 74.3, 71.2, 55.7, 55.6, 18.5, 17.3. HRMS (ESI): 
calcd for C29H29O7
+ [M+H]+ 489.1941, found 489.1942. IR 
(KBr, cm−1): 1712.6 (C=O), 1699 (C=O), 1685.5 (C=O).
2.2.2 | Continuous in vitro culture of P. 
falciparum blood forms
The chloroquine- resistant and mefloquine- sensitive W2 
clone of P. falciparum was cultivated as described by Trager 
and Jensen,[19] with some modifications. The antiplasmodial 
activity of neolignan derivatives was evaluated using triti-
ated hypoxanthine and anti- HRPII (histidine- rich protein) as-
says. At least two assays for each technique were performed. 
Each assay was performed in triplicate and chloroquine (as 
a reference drug) was used in each experiment as a control 
antimalarial.
Briefly, a 2% hematocrit of human red blood cells type A+ 
suspended in RPMI 1640 medium supplemented with 10% of 
human- inactivated sera type A+ was maintained in culture 
plates at 37°C in a gas mixture (5% CO2, 5% O2, and 90% N2 
atmosphere). The test of hipoxantine incorporation described 
previously [20] was used to evaluate drug activity, with some 
modifications. Briefly, before the test, the blood cultures 
were kept for at least 3 days in medium without hypoxan-
thine. The test was performed after sorbitol synchronization 
with ring stages [21] and then adjusted for 1% both parasitemia 
and hematocrit. The parasite suspension was placed in a plate 
containing the test compounds and incubated in culture con-
ditions for 24 hr when 3H- hypoxanthine was added, (0.5 μCi) 
(PerkinElmer, MA, EUA) to each well. Plates were incubated 
at 37°C for 18 hr and then frozen for at least 24 hr at −20°C 
and thawed to allow cell lysis. The plates were harvested 
[Tomtec 96- Harvester (Tomtec Inc., Handem, CT, USA)] 
in glass fiber filters (Wallac, Turku, Finland), which were 
placed in sample bags (Wallac) and subsequently immersed 
in scintillation fluid (Optiphase Supermix, Wallac). The [3H] 
uptake was measured in a 1450 Microbeta reader (Wallac).
An anti- HRPII immunoenzymatic assay was performed 
as described,[22] using 0.05% parasitemia and 1.5% hemato-
crit. The compounds were incubated at 37°C with parasite 
cultures for 72 hr. The culture was frozen and thawed for 
cell lysis to occur and release the HRPII protein present in 
live parasites. Parasite growth was evaluated by specific in-
teractions between the histidine- and alanine- rich parasite 
protein (HRPII) and commercially available monoclonal an-
tibodies (MPFM ICLLAB- 55A® and MPFG55P ICLLAB®, 
USA), which can be measured at 450 nm using SpectraMax 
340PC384 (Molecular Devices).
The anti- P. falciparum activity of neolignans was evalu-
ated using curve- fitting software (Microcal Origin Software 
5.0, Inc.) by comparing parasite growth in relation to drug- 
free control cultures, considered as 100% growth, and drug 
test cultures. A sigmoidal dose–response curve was generated 
and the half- maximal drug inhibitory concentration (IC50) of 
the parasite growth was determined. A molecule was consid-
ered active when the IC50 value was lower than 30 μm.
2.2.3 | Cytotoxicity assays and 
determination of drug selectivity indexes
The in vitro cytotoxicity assays were performed with cells 
derived from the hepatoma cell line HepG2A16 (ATTC, 
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Manassas, VA, USA), cultivated in 75- cm2 sterile culture 
flasks (Nunc) at 37°C in a 5% CO2 atmosphere. The cells 
were maintained in RPMI 1640 culture medium (Sigma- 
Aldrich Co., St. Louis, MO, USA) supplemented with 
40 mg/L gentamicin and 10% fetal bovine serum (FBS) 
(Invitrogen, Life Technologies, Carlsbad, CA, USA). When 
cell confluence reached 80%, they were trypsinized (0.25% 
trypsin–EDTA) (Gibco, Life Technologies, Carlsbad, CA, 
USA), washed, counted, diluted in complete medium at 
104 cells/well, and placed in a flat- bottomed 96- well plate 
(Corning, Santa Clara, CA, EUA), and then incubated for 
18 hr at 37°C to allow cell adhesion. The test and control 
compounds were added to the plates at various concentra-
tions (up to 1.000 μg/ml) and incubated for another 24 hr. 
MTT [3- (4,5- dimethylthiazol- 2- yl)- 2,5- diphenyltetrazoli
um bromide] at 5 mg/ml in water was added to each well, 
followed by another 3 hr of incubation at 37°C.[23,24] The 
supernatant was removed, 100 μl of DMSO was added to 
each well, and the reactions were read in a spectrophotom-
eter (Spectra Max 340PC384, Molecular Devices) with a 
570- nm filter, and a 630- nm filter for background. The cell 
viability was expressed as the percentage of the absorbance 
compared with untreated cells, subtracted from the appropri-
ate background. The minimum lethal dose (MLD50) of the 
F I G U R E  1  Electrostatic density map 
around of 3D structures of FP2 with E64 
(pink) and 10 (yellow) ligands [Colour 
figure can be viewed at wileyonlinelibrary.
com]
S C H E M E  1  Synthesis of neolignan 8.O.4′ derivatives. Reagents and conditions:(i) CHCl3, Br2, 0.5 hr, reflux; (ii) methyl ferulate; K2CO3, 
butanone, 12 hr, reflux; (iii) cinnamic acid or derivatives, K2CO3, butanone, 12 hr, reflux; (iv) 4- hydroxycinnamic acid, K2CO3, butanone, 12 hr, 
reflux; and (v) 4- hydroxybenzoic acid, K2CO3, butanone, 12 hr, reflux
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test compounds was determined as previously described[25]; 
each test was performed in duplicates. The selectivity index 
(SI), or therapeutic activity, was calculated only for the ac-
tive compounds, as the ratio between cytotoxicity and P. 
falciparum activity (MLD50/IC50), as described.
[20]
2.3 | Molecular docking
All structures were subjected to the geometry optimiza-
tion using the hybrid density functional (B3LYP) [26,27] and 
a basis set 6- 31G* using the Gaussian03 package.[28] The 
3D structure of enzyme FP2 complexed with the E64 (L- 
trans- epoxysuccinyl- leucylamido(4- guanidino)butane) was 
obtained from the Protein Data Bank (PDB accession code 
3BPF). All compounds (neolignan derivatives and inhibi-
tor E64) were submitted to docking studies using Molegro 
Virtual Docker (MVD) software. The enzyme cavity was 
detected with an active site radius of 6.0 Å from the side 
chain sulfur atom of residue Cys42, according to the litera-




































































CH3 330 ± 28 0.12 ± 0.01 0.18 ± 0.37 2,750
aSI = MLD50/IC50 obtained by [
3H]hypoxantine method which is a gold test among semi- automated techniques. 
MLD, minimum lethal dose. IC50, half- maximal drug inhibitory concentration. SD, standard deviation. NT, not 
tested.
T A B L E  1  Cytotoxicity assay (MLD50) 
against human hepatoma cells (line HepG2), 
in vitro activity against P. falciparum based 
on IC50 values and selectivity index (SI) of 
the neolignan derivatives
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acceptable drug/enzyme interaction was present. The follow-
ing parameters were used for the guided differential evolu-
tion algorithm: population size = 50, crossover rate = 0.9, 
scaling factor = 0.5, and max evaluations = 100,000. The 
algorithm used in the docking studies was MolDock Score, 
an adaptation of the differential evolution (DE) algorithm. 
The results of the molecular docking for neolignan deriva-
tives were compared with the experimental data.[29]
2.4 | Analysis of the molecular 
electrostatic potential
The maps of electrostatic density can be indicators of nucleo-
philic and electrophilic centers which control the strength of 
the connections, and of the unbound interactions and molecu-
lar reactivity. With the Adaptive Poisson–Boltzmann Solver 
(APBS) methodology,[30] it was possible to construct around 
the structure of the FP2 enzyme (Figure  1). The three- 
dimensional surfaces of the molecular electrostatic poten-
tial (MEP) were generated using the software Chimera and 
APBS,[31] with an ionic strength of 12 mm. Mapping of the 
electrostatic potential onto the molecular surface of the pro-
tein was performed with a potential range from −8 to 8 eV.
3 |  RESULTS
3.1 | Chemistry
Compounds 2,[32] 3,[33] and 6 [34]were synthesized as previ-
ously described. Compounds 7 and 8 were commercial, but 
their synthesis and spectral data are not available in the lit-
erature, and therefore, we described these in the experimental 
section. Neolignan derivatives 4, 5, 9, and 10 are new com-
pounds and were synthesized as shown in Scheme 1.
The commercially available aromatic ketones were con-
verted to the corresponding α- bromoketones 1a–c (Scheme 1, 
step i) in one step according to the methodology[35] and used 
without purification due to their strong teargas properties. 
All coupling reactions between α- bromoketones and phe-
noxy or carboxy nucleophiles generated in situ with anhy-
drous K2CO3 were performed in reflux of butanone as solvent. 
Compounds 7 (69% yield) and 8 (45% yield) were synthe-
sized through the reaction of the appropriate α- bromoketone 
with cinnnamic acid, 3,4- (methylenedioxy)cinnamic acid and 
3,4,5- trimethoxycinnamic acid, respectively (Scheme 1, step 
iii). Compound 9 was obtained via reaction of phenacyl bromide 
with methyl ferulate in 32% yield (Scheme  1, step ii). Treatment 
of 4- hydroxycinnamic acid and 4- hydroxybenzoic acid with 
anhydrous K2CO3 (Scheme 1, step iv) led to the formation of 
bi- nucleophiles (carboxy and phenoxy) in situ. Nucleophilic reac-
tions of bi- nucleophile generated from 4- hydroxycinnamic acid 
with phenacyl bromide and 4- methoxy- 8- bromopropiophenone 
afforded, respectively, compounds 4 (32% yield) and 10 (71% 
yield). Nucleophilic reactions of bi- nucleophile generated from 
4- hydroxybenzoic acid with phenacyl bromide resulted in com-
pound 5 at 34% yield (Scheme 1, step v). The reactions were 
monitored using TLC, and the products were purified by crys-
tallization from ethanol. All compounds were fully character-
ized using IR, 1H, and 13C NMR and EIMS, where their spectra 
were consistent with the assigned structures, and the details are 
given in Supporting information.
3.2 | Pharmacology
Among the nine neolignan derivatives evaluated in vitro 
against the W2 P. falciparum- resistant clone, only deriva-
tives 9 and 10 exhibited IC50 of 26.6 and 12.1 μm, respec-
tively, by 3H- hypoxanthine incorporation assay (Table 1).
3.3 | Cytotoxic activity and selectivity index
The nine neolignans tested showed MLDs above 1,500 μm, 
thus indicating that they are non- toxic to HepG2 cells 
(Table 1). The active derivatives 10 (MLD50 above 
1,545.5 μm) and 9 (MLD50 above 3,064.3 μm) showed selec-
tivity indexes above 128.8 and 115.2, respectively.
3.4 | Molecular docking
Co- crystallized ligand (E64) was re- docked to their target 
protein (FP2) to validate the docking protocol. When com-
pared with the crystal structure, the docked conformation 
of E64 gave RMSD of 0.15 Å and had a MolDock score of 
−133.2 kcal/mol, shown in Figure 2. These results illustrate 
F I G U R E  2  Superposition of the docked (blue) and crystal 
structure (pink) conformations of E64 in the active site of FP2 [Colour 
figure can be viewed at wileyonlinelibrary.com]
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a good adjustment between the theoretical and experimental 
data.[29]
Docked conformations of derivatives 9 and 10 were ranked 
based on their MolDock score and the best conformation 
(Table 2). The RMSD value obtained for the two complexes 
was 0.19 and 0.12 Å, and the score values were −102.2 and 
−111.7 kcal/mol, respectively. These values are relatively 
close to the score value of inhibitor E64 (−133.2 kcal/mol). 
Interestingly, the observed activities against clone W2 were 
26.6, 12.1, and 3.0 μm, for 9, 10, and E64, respectively.
In this study, the carbonyl group (L-trans-Epoxysuccinyl) 
and the amide group (leucylamido) of E64 inhibitor were 
located near the catalytic cysteine residue (Cys42), trypto-
phan (Trp43), and glycine (Gly83) of the FP2. In addition, 
the oxyanion hole located in the S2 cavity was occupied by 
the carbonyl group (L-trans-Epoxysuccinyl), which interacts 
with the thiol group of Cys42 at a distance of 2.5 Å. This 
carbonyl group also interacts through hydrogen bonds with 
the aromatic ring of Trp43 at 2.9 Å. For the amide group 
(leucylamido), two interactions with amine and carboxyl 
group of Gly83 at 3.2 and 2.9 Å, respectively, were observed 
(Figure 3a).
Figure 3b shows the predicted binding site of compound 
10 in the F2 catalytic site suggested by molecular docking. 
In this complex (FP2- 10), the ester group of derivate 10 also 
occupies the oxyanion hole of the cavity S2, interacting with 
amine and thiol groups of Cys42 at bond lengths of 3.0 and 
3.1 Å, respectively, same as for the E64 inhibitor. Moreover, 
a series of hydrogen bonds can be observed between methoxy 
groups of derivate 10 and the residues of His174, Ser149, and 
Ile85 situated within cavities S1′ and S2, similar to previous 
reports,[36,37] being the bond length 3.1, 2.9, and 2.9 Å, re-
spectively (Figure 3b). Lastly, derivate 9 showed only one in-
teraction at a distance of 2.9 Å with residue Ile85 (Figure 3c) 
evidencing the low potency against FP2 as well as its IC50 
value.
4 |  DISCUSSION
The neolignans constitute a class of chemical substances 
with described biological actions against leishmaniasis, can-
cer, and other diseases.[12–15,38] Some neolignans and their 
derivatives have shown antimalarial activity at low con-
centration.[39,40] Derivate 9 in this study exhibited in vitro 
activity, with IC50 of 12.1 μm, similar to other neolignan 
derivatives such as virolongin A (IC50 of 14.9 μm) against 
chloroquine- resistant P. falciparum (clone Dd2).[36] These 
derivatives have a similar structure to compound 10 with the 
presence of three benzene nuclei. Furthermore, the presence 









2 −82.3 −2.2 2
3 −77.9 −2.0 2
4 −90.1 0 0
5 −90.5 −0.4 1
6 −80.4 −2.3 2
7 −91.5 −3.2 2
8 −82.6 −1.9 1
9 −102.2 −4.1 1
10 −111.7 −7.3 4
E64a −133.2 −8.5 4
aExperimental value obtained by Kerr and Lee et al.[27].
F I G U R E  3  Hydrogen bonds formed by the E64 (pink) and derivatives 10 (yellow) and 9 (orange) with the active site residues of the 
falcipain- 2 (green) [Colour figure can be viewed at wileyonlinelibrary.com]
(a) (b) (c)
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of methoxyl and the absence of chlorine as substituents in 
the neolignan derivatives are important for good antimalarial 
activity.[37,40,41] In previous work [18] where active lignans 
were evaluated against a chloroquine- resistant P. falciparum 
strain, the importance of the methoxy substituent for good 
antiparasitic activity was demonstrated. Most lignoids were 
not cytotoxic (MLD50 > 1,500 μm) and are therefore good 
new antimalarial candidates as suggested previously.[17] The 
selectivity index was above 100 μm for two new compounds 
tested, the neolignan derivatives 9 and 10.
The active site of FP2 can be divided into four cavities 
denominated S1, S1′, S2, and S3 (Figure 1), and is located 
in a cleft between the two structurally distinct domains, with 
catalytic triad of Cys42, Asn173, and His174.[29] Derivate 
10 is a potential inhibitor of FP2, and as can be seen in 
Figure 1, this derivative effectively occupied cavities S1 and 
S2. Furthermore, it establishes several interactions with cat-
alytic FP2 residues localized in cavity S2 (Figure 3), com-
monly observed among cysteine protease inhibitors.[42] The 
S2 site is a predominantly hydrophobic region where residues 
were shown to be preferentially linked to groups of the sub-
strate,[43] but can also interact with hydrophilic groups. This 
fact explains the interactions of the methoxy groups of deri-
vates 9 and 10 in this cavity.[44]
5 |  CONCLUSIONS
Nine neolignans tested were not toxic to HepG2 cells 
exhibiting minimal lethal doses (MLD50) greater than 
1,500 μm. Only derivatives 9 and 10 showed activity against 
chloroquine- resistant P. falciparum clone W2. Interactions 
and score values obtained by molecular docking techniques 
for complexes formed with neolignans and FP2 were sat-
isfactory when compared to the crystallographic E64- FP2 
complex. These results show that neolignans are promising 
prototypes to be considered in the search of potent new de-
rivatives against malaria parasites, as well as less toxic prod-
ucts for safe therapy.
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